Slide 18 June 2004NCAC Society of Toxicology1 Detecting Liver Injury: Drug-Induced or Not ? John R. Senior, M.D., Hepatologist Associate Director for Science Office of Pharmacoepidemiology…

1. The Name Game : How the USPTO and Changing FDA Approval Processes Affect Protection ofNew Drug Names Lisa M. Tittemore, Esq.Keith E. Toms, Esq. Bromberg & Sunstein…

1. More Adventures:Placebo Database John R. Senior, M.D., Hepatologist Associate Director for Science Office of Pharmacoepidemiology & Statistical Science Food and Drug…

Slide 1 28 January 2005FDA/CDER-AASLD-PhRMA HepTox Steering Group 1 Recognizing Drug-Induced Liver Injury (DILI) in Exposed Populations John R. Senior, M.D. Associate Director…

Slide 1 The United States Drug Safety Paradigm Stephen A. Goldman, M.D., FAPM, FAPA Former Medical Director, MedWatch, FDA Stephen A. Goldman Consulting Services, L.L.C.…

Recognizing Drug-Induced Liver Injury (DILI) in Exposed Populations John R. Senior, M.D. Associate Director for Science Office of Pharmacoepidemiology and Statistical Science…

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005 Outline Drug Safety Oversight Board (DSOB,…